Editorial

COVID-19 and Rheumatic Diseases: It Is Time to Better Understand This Association

Claudia D.L. Marques1, on behalf of the ReumaCoV Brasil Study Group

The coronavirus disease 2019 (COVID-19; caused by the SARS-CoV-2 virus), which by the end of 2019 was completely unknown to clinicians, brought uncertainties and challenges never before experienced in the modern era. Since the World Health Organization declared the pandemic on March 11, 20201, more than 50,000,000 confirmed cases have been reported worldwide, and more than 1,200,000 individuals have died from the disease2.

In this scenario, many clinical questions have emerged from a rheumatologic standpoint: Are patients with immune-mediated rheumatic diseases (IMRD) more likely to get infected by SARS-CoV-2? Will patients with rheumatic diseases develop more severe forms of COVID-19? How should we manage immunosuppressors and biological therapy? Is there a chance of reactivation of IMRD after COVID-19? Will a SARS-CoV-2 infection trigger an autoimmune disease? To date, these questions remain unanswered.

Although patients with IMRD are known to be at higher risk of infection—attributed mainly to disease activity, comorbidities, and immunosuppressive therapy—the first published papers addressing COVID-19 in patients with IMRD, based on the clinical information published up to that time, indicated there was no consistent evidence that these patients were at higher risk compared to those with other comorbidities3,4. Since then, numerous papers about COVID-19 in patients with IMRD have been published, but there are still many unanswered questions.

The first question that has not yet been fully answered is related to the prevalence of COVID-19 in the IMRD population. The results of initial published studies showed comparable rates to those in the general population, and even lower rates in some studies5,6,7,8. However, a recent Italian study with 1641 patients with IMRD, from 3 Italian geographical areas with different prevalence of COVID-19, showed significantly higher rates of SARS-CoV-2 infection compared to the general Italian population, mainly due to patients’ increased susceptibility to infections and by the high exposure to the virus at medical facilities before the restriction measures on individual movement9. Additionally, higher percentages of COVID-19 were observed in patient cohorts with connective tissue diseases, especially systemic lupus erythematosus10,11.

The second still-unanswered question is related to COVID-19 severity in IMRD. Faye, et al, as described in this issue of The Journal of Rheumatology12, conducted a retrospective cohort study of patients hospitalized with COVID-19, comparing their outcomes to patients with autoimmune diseases and age- and sex-matched controls in New York (USA) during the first months of the pandemic. The primary outcome was a composite of adverse events comprising death, intubation, and admission to an intensive care unit (ICU); the secondary outcome was time to in-hospital death. Among 1186 patients hospitalized with COVID-19 during the study period, 62 patients with autoimmune diseases were identified, with rheumatoid arthritis being the most frequent. The results demonstrated that this group of patients with autoimmune diseases was not at an increased risk for ICU admission, intubation, or death; instead, age and presence of comorbidities were the primary predictors of adverse outcomes.

Although the study is well analyzed, these results should be interpreted with caution and should not be generalized to patients with IMRD worldwide. The sample size is small and is contaminated with other disorders outside the spectrum of rheumatic diseases. In addition, there is no information on disease activity at the time of the SARS-CoV-2 infection. As has occurred in other studies of COVID-19 in IMRD performed at the beginning of the pandemic, it is probably a bias of inclusion.

See COVID-19 and Autoimmune Disease, page 454
A growing body of evidence has shown that the evolution of COVID-19 in patients with IMRD may be more severe, with worse outcomes, particularly in studies with larger samples. Gianfrancesco, et al.12, from the COVID-19 Global Rheumatology Alliance, found that although most individuals with rheumatological diseases or on immunosuppressive therapies recover from COVID-19, exposure to moderate- to high-dose glucocorticoids (GC) was associated with a higher risk of hospitalization. Anti–tumor necrosis factor therapy was associated with a decreased risk of hospitalization in patients with rheumatic disease. Freites Nuñez, et al.13 observed a high percentage of patients with autoimmune inflammatory rheumatic diseases and COVID-19–related hospital admission. The patients were mainly elderly, with comorbidities and a systemic autoimmune condition. Ugarte-Gil, et al.14 showed that Latin American patients with IMRD had a higher rate of acute respiratory distress syndrome (ARDS) and used GC more frequently and at a higher dose, although their mortality rate was similar to that of patients from the rest of the world.

The third question is the association between the use of corticosteroids (CS) and immunosuppressive drugs, and COVID-19 outcomes. In the study by Faye, et al.15, two results are related to the use of CS and deserve to be highlighted: (1) unlike other studies, chronic CS use was not associated with adverse outcomes; and (2) inpatient initiation of CS or hydroxychloroquine (HCQ) was associated with adverse outcomes. Evidence arising from larger cohorts of patients with IMRD has associated the chronic use of GC with worse COVID-19 outcomes.16-18 Patients with IMRD treated with high-dose CS are at significant risk of other serious infections.19 In addition to this higher susceptibility, these patients can potentially develop a more severe course of infection due to the variety of metabolic and cardiovascular complications related to cortisol excess.20 Thus, it is expected that this association actually exists, and the lack of this evidence in some studies is probably a result of different populations in different scenarios.

Although the studies that evaluated the use of HCQ have not demonstrated its effectiveness as a protective or therapeutic agent, its use also seems to have no association with severe outcomes.21 Some studies using CS in the acute phase of COVID-19 have also shown their effectiveness in controlling inflammation markers, particularly in cases of ARDS.22 Thus, the association of worse outcomes with intrahospital use of CS and HCQ could be related to its use in more severe patients, perhaps late, in an attempt to improve the patient’s condition, when there was little knowledge about the treatment of COVID-19.

Nine months have passed since the beginning of the COVID-19 pandemic, and the amount of information produced has been impressive and frighteningly fast. However, evidence of COVID-19 risks and outcomes in patients with IMRD is still limited, and any conclusions at this moment will be precipitated and unsafe. More research in the field is necessary, including epidemiological studies, prospective cohorts, and appropriately controlled clinical trials. At this stage, it is impossible to draw any conclusions regarding differences in COVID-19 risks and outcomes across different autoimmune diseases and the various immunomodulatory therapies used for them. Therefore, we must continue to find information to better understand the interface between COVID-19 and IMRD.

REFERENCES


